Xenon pharmaceuticals inc. (XENE)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net loss

-11,376

-8,871

-10,007

-11,341

-8,558

-14,383

-7,801

-3,755

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-7,517

-6,004

-7,714

-6,016

-3,263

-3,937

-3,827

1,168

-9,156

1,224

9,191

1,230

1,373

Items not involving cash:
Depreciation

146

104

100

79

141

143

152

150

147

168

169

165

166

167

249

282

284

262

285

207

205

183

175

175

Amortization of discount on term loan

137

133

130

125

128

-8

92

72

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax recovery

-60

-62

-44

33

-11

-33

-24

-37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

1,357

612

464

491

575

687

700

663

593

567

598

478

519

636

414

592

474

-191

-1,773

5,219

199

188

187

186

Deferred tenant inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15

-16

-16

-16

-17

-16

-17

Unrealized foreign exchange (gain) loss

141

-64

202

23

-377

137

-139

-267

-111

766

493

326

-711

-497

248

2,260

-1,416

-3,133

787

-3,140

-20

-44

29

-37

Gain on termination of collaboration agreement (note 13c)

-

-

-

-

0

0

0

4,398

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

599

39

35

-20

69

-25

-284

-40

309

-72

6

-11

-393

-61

273

60

46

92

-1,027

996

58

-194

-71

-2

Prepaid expenses and other current assets

1,028

314

-133

-389

-311

1,046

-242

435

-370

347

-186

-404

65

-732

178

-82

-171

1,606

-1

-220

546

45

11

-29

Prepaid expenses, long term

-

-

-

-

-

-

0

-230

12

-67

16

-139

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

847

1,306

828

1,560

-136

1,257

678

-1,016

316

-645

140

186

-461

944

161

-160

-206

573

760

-1,110

-96

740

139

-265

Net cash used in operating activities

19,735

-7,067

-8,633

-8,667

-7,242

-13,725

-5,538

-8,219

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-157

-2,356

-3,122

-3,089

-3,055

-3,883

-4,194

-3,971

-2,362

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-6,460

-4,670

-4,524

-5,429

-4,944

-5,247

-4,885

-2,424

-5,547

-2,951

6,284

-2,225

-842

Purchases of property, plant and equipment

595

45

265

335

170

19

137

181

63

14

101

137

28

46

122

83

143

218

106

84

776

256

17

480

Purchase of marketable securities

64,430

11,888

29,851

34,325

26,872

32,219

9,763

8,148

-

-

-

-

-

-

-

-

-

-

-

-

-80

12,388

368

2,578

Proceeds from marketable securities

4,759

19,682

23,374

27,628

14,486

8,890

11,840

13,306

11,592

-75

31,715

9,384

-

-

-

-

0

8,927

243

1,575

1,736

7,235

1,848

2,720

Net cash used in investing activities

-60,266

7,749

-6,742

-7,032

-12,556

-23,348

1,940

4,977

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

9,247

-32,226

-111

-15,422

-83

-143

8,709

137

1,491

1,040

-5,409

1,463

-338

Issuance of common shares, net of issuance costs (note 11a)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86

127

42,634

6

-1

5

Deferred financing fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

228

575

332

398

Issuance of common shares pursuant to exercise of stock options

35

18

11

58

26

80

63

119

0

0

3

174

48

2

38

44

-

-

-

-

-

-

-

-

Net cash provided by financing activities

27,431

18

11

58

34

77,429

34,009

119

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

174

48

23,834

38

44

38

27

86

127

42,419

-569

-333

-393

Effect of exchange rate changes on cash and cash equivalents

-

-

259

67

-

-

-176

-163

-60

313

396

104

-192

-274

-41

2,396

-1,466

-2,728

630

-2,180

-2,213

-1,662

1,235

-1,430

Increase (decrease) in cash and cash equivalents

-

-

-15,105

-15,574

-

-

30,235

-3,286

5,798

-8,402

2,930

3,065

-37,040

18,925

-20,854

-2,587

-6,818

1,123

-1,571

-6,109

38,295

-1,356

140

-3,003

Supplemental disclosures:
Interest paid

215

234

238

230

223

174

93

71

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest received

278

669

560

709

549

229

148

141

196

87

402

55

80

57

92

112

109

282

147

121

-

-

-

-

Cash paid for operating lease

165

155

156

158

159

161

152

152

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest received

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

201

113

125

Supplemental disclosures of non-cash transactions:
Fair value of stock options exercised on a cashless basis

-

345

2

7

-

900

36

176

-

-

6

19

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of preferred shares in exchange for common shares (note 11d)

-

-

-

-

0

0

0

21,825

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common shares on conversion of subscription rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

92

5

13

14

Fair value of options exercised on a cashless basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

355

120

69

-

-

-

-

Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]
Termination of Teva agreement through cancellation of common shares (note 13c)

-

-

-

-

0

0

0

4,470

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-